Curvietto, Marcello

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caracò, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., et al. (2014) · Cancer Immunology, Immunotherapy

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 253

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients

Grimaldi, A., Simeone, E., Festino, L., Giannarelli, D., Palla, M., Caracò, C., Curvietto, M., Esposito, A., Grimaldi, M., Mozzillo, N., et al. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 11

Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy.

Dearden, H. C., Au, L., Wang, D. Y., Zimmer, L., Eroglu, Z., Smith, J. L., Curvietto, M., Khoo, C., Atkinson, V., Lo, S., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2